Symbols

EVAX

Evaxion·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EVAX

Evaxion A/S

A clinical-stage biotech company developing AI-powered immunotherapies

Industry

Pharmaceutical

Established Date

08/11/2008

Listing Date

02/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.evaxion.ai

Security Type

Depository Receipts (Ordinary Shares)

Office address

Dr. Neergaards Vej 5F, DK-2970 Horsholm, Denmark

Business

Introduction

Evaxion A/S was established on August 11, 2008 under the laws of the Kingdom of Denmark. The Company is a clinical-stage company that leverages its proprietary artificial intelligence or AI, technology, engineering expertise and drug development knowledge to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.

Company Financials

EPS

EVAX has released its 2025 Q2 earnings. EPS was reported at -0.02, versus the expected -0.58, beating expectations. The chart below visualizes how EVAX has performed over recent quarters, highlighting trends in earnings surprises.